NCT07682675
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07682675
Title Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck (ZANACC)
Acronym ZANACC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNICANCER
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.